Pub Date : 2024-06-19eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000171
Wenjing Ni, Junping Shi, Jie Li
{"title":"Epidemiology, natural history, and management of patients with CHB concurrent with MASLD.","authors":"Wenjing Ni, Junping Shi, Jie Li","doi":"10.1097/CLD.0000000000000171","DOIUrl":"10.1097/CLD.0000000000000171","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11186830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-14eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000156
Huey-Ling Chen
{"title":"Management of chronic hepatitis B infection in children.","authors":"Huey-Ling Chen","doi":"10.1097/CLD.0000000000000156","DOIUrl":"10.1097/CLD.0000000000000156","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-14eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000183
Gamal Shiha, Riham Soliman, Ayman Hassan, Ahmed Farahat, Ahmed Salem, Amr Taha, Ramy Sabry, Ahmed Geith, Ahmed Elshawaf, Nabiel Mikhail
It is alarming that globally, only 2.2% (6.6 million) of patients with chronic hepatitis B (CHB) received treatment in 2019. One contributing factor to this low treatment rate is the complexity and restrictive nature of clinical practice guidelines. Since 1998, we have adopted a "treat-all" approach to patients with CHB. A retrospective study was conducted involving patients with CHB who received treatment from 1998 to 2020 at 2 institutions in Egypt. These patients underwent evaluation through various clinical and laboratory methods, which included testing for liver enzymes and HBV DNA. The study analyzed 1825 patients with HBV, finding that 27.4% had viremia levels under 2000 IU/mL. Most (88%) were HBeAg-negative, with 12% positive. A large portion (77.6%) had normal alanine aminotransferase levels, though 5.6% exceeded twice the upper limit of normal. About 14.2% were diagnosed with liver cirrhosis, and 9.6% with F3 stage fibrosis at enrollment. Notably, 2% (25 cases) lost HBsAg over a median of 52 months. Patients with HBV DNA <2000 IU/mL had a higher HBsAg loss rate (4.2%) compared to those with levels >2000 IU/mL (1.3%). During follow-up, 9.5% (117 patients) experienced decompensation, with a higher incidence in those with HBV DNA <2000 IU/mL (16.8%) than those >2000 IU/mL (7.1%). HCC developed in 5.2% of patients with lower HBV DNA and 2.6% with higher levels, showing significant differences. Liver-related deaths occurred in 2.8% of the cohort, with a slightly higher rate in those with lower initial HBV DNA levels (3.5% vs. 2.5%). The findings suggest a paradigm shift in CHB management toward early and broader eligibility for antiviral therapy. This could improve patient outcomes and address the global treatment gap in CHB management, especially in regions with high CHB prevalence.
{"title":"Management of patients with CHB outside the guidelines: Insights from Egyptian cohort with long-term follow-up.","authors":"Gamal Shiha, Riham Soliman, Ayman Hassan, Ahmed Farahat, Ahmed Salem, Amr Taha, Ramy Sabry, Ahmed Geith, Ahmed Elshawaf, Nabiel Mikhail","doi":"10.1097/CLD.0000000000000183","DOIUrl":"10.1097/CLD.0000000000000183","url":null,"abstract":"<p><p>It is alarming that globally, only 2.2% (6.6 million) of patients with chronic hepatitis B (CHB) received treatment in 2019. One contributing factor to this low treatment rate is the complexity and restrictive nature of clinical practice guidelines. Since 1998, we have adopted a \"treat-all\" approach to patients with CHB. A retrospective study was conducted involving patients with CHB who received treatment from 1998 to 2020 at 2 institutions in Egypt. These patients underwent evaluation through various clinical and laboratory methods, which included testing for liver enzymes and HBV DNA. The study analyzed 1825 patients with HBV, finding that 27.4% had viremia levels under 2000 IU/mL. Most (88%) were HBeAg-negative, with 12% positive. A large portion (77.6%) had normal alanine aminotransferase levels, though 5.6% exceeded twice the upper limit of normal. About 14.2% were diagnosed with liver cirrhosis, and 9.6% with F3 stage fibrosis at enrollment. Notably, 2% (25 cases) lost HBsAg over a median of 52 months. Patients with HBV DNA <2000 IU/mL had a higher HBsAg loss rate (4.2%) compared to those with levels >2000 IU/mL (1.3%). During follow-up, 9.5% (117 patients) experienced decompensation, with a higher incidence in those with HBV DNA <2000 IU/mL (16.8%) than those >2000 IU/mL (7.1%). HCC developed in 5.2% of patients with lower HBV DNA and 2.6% with higher levels, showing significant differences. Liver-related deaths occurred in 2.8% of the cohort, with a slightly higher rate in those with lower initial HBV DNA levels (3.5% vs. 2.5%). The findings suggest a paradigm shift in CHB management toward early and broader eligibility for antiviral therapy. This could improve patient outcomes and address the global treatment gap in CHB management, especially in regions with high CHB prevalence.</p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-14eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000230
Agnieszka Maniak, Nancy Reau
{"title":"A severe case of hypercalcemia in a patient with presumed cryptogenic cirrhosis.","authors":"Agnieszka Maniak, Nancy Reau","doi":"10.1097/CLD.0000000000000230","DOIUrl":"10.1097/CLD.0000000000000230","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-14eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000232
Cyriac Abby Philips, Shiv K Sarin
{"title":"Noncirrhotic portal hypertension-Historical perspectives bring clarity to the entity and its management.","authors":"Cyriac Abby Philips, Shiv K Sarin","doi":"10.1097/CLD.0000000000000232","DOIUrl":"10.1097/CLD.0000000000000232","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-14eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000222
Manisha Verma, Archita P Desai
{"title":"The role of patient-reported outcomes in a patient-centered care model for managing chronic liver diseases.","authors":"Manisha Verma, Archita P Desai","doi":"10.1097/CLD.0000000000000222","DOIUrl":"10.1097/CLD.0000000000000222","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Review of immune therapy in HCC: Where are we now and what is the future?","authors":"Valentina Zanuso, Angelo Pirozzi, Giulia Tesini, Lorenza Rimassa","doi":"10.1097/CLD.0000000000000149","DOIUrl":"10.1097/CLD.0000000000000149","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-14eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000199
Helgi K Björnsson, Einar S Björnsson
{"title":"Hepatotoxicity in inflammatory bowel disease: Immunomodulators, biologics, and beyond.","authors":"Helgi K Björnsson, Einar S Björnsson","doi":"10.1097/CLD.0000000000000199","DOIUrl":"10.1097/CLD.0000000000000199","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-14eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000184
Andrew P Kassa, Jonathan G Stine
{"title":"(P)rehabilitation in advanced chronic liver disease (advCLD): From basic exercise concepts to implementation challenges.","authors":"Andrew P Kassa, Jonathan G Stine","doi":"10.1097/CLD.0000000000000184","DOIUrl":"10.1097/CLD.0000000000000184","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-14eCollection Date: 2024-01-01DOI: 10.1097/CLD.0000000000000231
Dirk J van Leeuwen
{"title":"Ethics in hepatology: A professional and very personal journey.","authors":"Dirk J van Leeuwen","doi":"10.1097/CLD.0000000000000231","DOIUrl":"10.1097/CLD.0000000000000231","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号